Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells therapy(NIH)

N/A

Report date: 2025/03/26 20:01:25

Base Information

Drug NameAnti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells therapy(NIH)
Drug Alias NameTNhYP218TNhYP217TNhYP-217TNhYP-218
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-MesothelinT lymphocyte replacements
TargetsMesothelin
Therapy Area/IndicationsThymus NeoplasmsLung NeoplasmsOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsThymus NeoplasmsLung NeoplasmsOvarian Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A